In last trading session, ImmunityBio Inc (NASDAQ:IBRX) saw 6.33 million shares changing hands with its beta currently measuring 0.70. Company’s recent per share price level of $3.64 trading at -$0.26 or -6.67% at ring of the bell on the day assigns it a market valuation of $2.66B. That closing price of IBRX’s stock is at a discount of -189.29% from its 52-week high price of $10.53 and is indicating a premium of 37.36% from its 52-week low price of $2.28.
For ImmunityBio Inc (IBRX), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Upright in the red during last session for losing -6.67%, in the last five days IBRX remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $3.64 price level, adding 14.75% to its value on the day. ImmunityBio Inc’s shares saw a change of 42.19% in year-to-date performance and have moved 12.35% in past 5-day. ImmunityBio Inc (NASDAQ:IBRX) showed a performance of 13.04% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 39.33% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -64.84% in reaching the projected high whereas dropping to the targeted low would mean a loss of -64.84% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.17% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 30.43% while estimates for its earnings growth in next 5 years are of 32.58%.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
VANGUARD GROUP INC is the top institutional holder at IBRX for having 13.83 million shares of worth $87.42 million. And as of 2024-06-30, it was holding 2.0558 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 11.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6978 of outstanding shares, having a total worth of $72.19 million.
